Nebenwirkungen · Betmiga
Betmiga 25 mg prolonged-release tablets Betmiga 50 mg prolonged-release tablets · Abschnitt 4.8 · PDF-Seite 8
HOS-125588 · Präparat HOS-096097
The safety of Betmiga was evaluated in 8 433 adult patients with OAB, of which 5 648 received at least one dose of mirabegron in the phase 2/3 clinical program, and 622 patients received Betmiga for at least 1 year (365 days). In the three 12-week phase 3 double blind, placebo-controlled studies, 88% of the patients completed treatment with this medicinal product, and 4% of the patients discontinued due to adverse events. Most adverse reactions were mild to moderate in severity.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-27T15:00:59Z · SHA-256 558bb9d8a6fe7ed39b4c0f0949d9a92ad4ac9abd83d84e765873084c7eafe957 · Passage 92ea5c8cba1cacbf5ef8fde0e727c74f76c0afca336f44f6cfa44eab44a1c1b9 · Zeichen 31–514 im Abschnitt